JAMES GALLO: Open Payments
NPI 1801978622 · WARWICK, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$694 in 14 payments from 8 companies in 2025. Trend: 2023 $674 · 2024 $272 · 2025 $694
Food & beverage: $694
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $232 |
| Vanda Pharmaceuticals Inc. | 2 | $141 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Neurocrine BioSciences, Inc. | 1 | $122 |
| Braeburn Inc. | 1 | $23 |
| Corium, LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
Products named: VRAYLAR, FANAPT, CAPLYTA, INGREZZA, BRIXADI, Azstarys, REXULTI, WELLBUTRIN.
Industry payments across RI — which companies pay providers there.
